Rebound hypercalcemia post denosumab therapy in an 8-year-old child: A case report

Denosumab has been successfully used as an off-label therapy for the treatment of pediatric aneurysmal bone cysts. Severe hypercalcemia after cessation of denosumab therapy has been reported in a few case reports in the literature. It is imperative to understand the causative factors, management options, and preventive strategies of rebound hypercalcemia after denosumab withdrawal in pediatric patients. We report an 8-year-old male child who presented to us with severe rebound hypercalcemia 3 months post cessation of denosumab therapy.